Marker Therapeutics, Inc. (MRKR) Stock Price & Analysis

Marker Therapeutics, Inc. (MRKR) fell 3.42% to USD 1.41 as of June 10, 2026 at 10:41 UTC, according to Nexqual real-time market data.

MRKR last closed at USD 1.46; the session ranged USD 1.4–1.47 on volume of 27,302 shares. Market capitalization is $23.51M, with a 52-week range of USD 0.81–4.07 (NCM). Source: Nexqual, June 10, 2026 at 10:41 UTC.

Key Statistics (as of June 10, 2026 at 10:41 UTC)

Technical Analysis (MRKR)

Nexqual's technical model rates MRKR "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 10:41 UTC.

Analyst Ratings (MRKR)

Wall Street analysts rate MRKR "None" based on 3 analysts, with a mean price target of USD 7.87 (range USD 5.6–10), per Nexqual as of June 10, 2026 at 10:41 UTC.

Earnings (MRKR)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 10:41 UTC.

Financials & Fundamentals (MRKR)

Source: Nexqual, June 10, 2026 at 10:41 UTC.

Financial Health Score (MRKR)

Nexqual rates Marker Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:41 UTC.

Ownership (MRKR)

Source: Nexqual, June 10, 2026 at 10:41 UTC.

Leadership (MRKR)

Marker Therapeutics, Inc. is led by Juan F. Vera (age 45), Co-Founder, CEO, President, Treasurer, Secretary & Director, per Nexqual as of June 10, 2026 at 10:41 UTC.

Major Backers & Investors (MRKR)

Notable institutional backers of Marker Therapeutics, Inc. include NEA Management Company, LLC, Blue Owl Capital Holdings LP, Aisling Capital Management LP, according to Nexqual as of June 10, 2026 at 10:41 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 10:41 UTC.

From Marker Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• BCM Exclusive License Agreement On March 16, 2018, we entered into an exclusive license agreement, or the BCM License Agreement, with BCM, under which we received a worldwide, exclusive license to BCM's rights in and to certain intellectual property rights, including European patent EP 2470644 (estimated expiration date August 24, 2030), to develop and commercialize MAR-T cell product candidates.
• Trade Secrets We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-oncology.
• We believe that by targeting up to six tumor-specific antigens, our MAR-T cell approach facilitates robust killing of targeted cancer cells and minimizes tumor escape. ​ ​ We believe our proprietary MAR-T cell platform may have meaningful advantages over current CAR and TCR-engineered cell therapy approaches.
• Competition may also arise from: 12 Table of Contents We face, and will continue to face, competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to drug candidates or proprietary technology.

Partnerships

• In connection therewith, we entered into a settlement and release agreement with Cell Ready pursuant to which we paid Cell Ready approximately $453,000 and we provided one another with mutual releases of all claims associated with any and all agreements between Marker and Cell Ready.
• Clinical Development of Our MAR-T Cell Therapies by BCM The following clinical trials were conducted by BCM pursuant to our strategic alliance.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:41 UTC. This page is informational and not investment advice.